Literature DB >> 34776418

Differentiation of Pediatric-Onset Duchenne and Becker Muscular Dystrophy Subphenotypes Using Data from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet).

Jennifer G Andrews1, Molly M Lamb2, Kristin M Conway3, Natalie Street4, Christina Westfield5, Emma Ciafaloni6, Dennis Matthews7, Shree Pandya6.   

Abstract

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) phenotypes are used to describe disease progression in affected individuals. However, considerable heterogeneity has been observed across and within these two phenotypes, suggesting a spectrum of severity rather than distinct conditions. Characterizing the phenotypes and subphenotypes aids researchers in the design of clinical studies and clinicians in providing anticipatory guidance to affected individuals and their families. Using data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), we used K-means cluster analysis to group phenotypically similar males with pediatric-onset dystrophinopathy. We identified four dystrophinopathy clusters: Classical BMD, Classical DMD, late ambulatory DMD, and severe DMD. The clusters that we identified align with both 'classical' and 'non-classical' dystrophinopathy described in the literature. Individuals with dystrophinopathies have heterogenous clinical presentations that cluster into phenotypically similar groups. Use of clinically-derived phenotyping may provide a clearer understanding of disease trajectories, reduce variability in study results, and prevent exclusion of certain cohorts from analysis. Findings from studying subphenotypes may ultimately improve our ability to predict disease progression.

Entities:  

Keywords:  Duchenne; MD STARnet; becker; cluster analysis; dystrophinopathy; phenotype; subphenotype

Mesh:

Year:  2022        PMID: 34776418      PMCID: PMC9059491          DOI: 10.3233/JND-210739

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  24 in total

Review 1.  The muscular dystrophies.

Authors:  Kevin M Flanigan
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

2.  [Phenotypic heterogeneity and phenotype-genotype correlations in dystrophinopathies: Contribution of genetic and clinical databases].

Authors:  V Humbertclaude; D Hamroun; M-C Picot; K Bezzou; C Bérard; O Boespflug-Tanguy; C Bommelaer; E Campana-Salort; C Cances; B Chabrol; M-C Commare; J-M Cuisset; C de Lattre; C Desnuelle; B Echenne; C Halbert; O Jonquet; A Labarre-Vila; M-A N'guyen-Morel; M Pages; J-L Pepin; T Petitjean; J Pouget; E Ollagnon-Roman; C Richelme; F Rivier; S Sacconi; V Tiffreau; C Vuillerot; C Béroud; S Tuffery-Giraud; M Claustres
Journal:  Rev Neurol (Paris)       Date:  2013-08-14       Impact factor: 2.607

3.  Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.

Authors:  Birol Balaban; Dennis J Matthews; Gerald H Clayton; Terri Carry
Journal:  Am J Phys Med Rehabil       Date:  2005-11       Impact factor: 2.159

4.  Diagnostic Accuracy of Phenotype Classification in Duchenne and Becker Muscular Dystrophy Using Medical Record Data1.

Authors:  Jennifer G Andrews; Molly M Lamb; Kristin Conway; Natalie Street; Christina Westfield; Emma Ciafaloni; Dennis Matthews; Christopher Cunniff; Shree Pandya; Deborah J Fox
Journal:  J Neuromuscul Dis       Date:  2018

5.  Clinical studies in benign (Becker type) X-linked muscular dystrophy.

Authors:  A E Emery; R Skinner
Journal:  Clin Genet       Date:  1976-10       Impact factor: 4.438

6.  Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

Authors:  Isabelle Desguerre; Christo Christov; Michele Mayer; Reinhard Zeller; Henri-Marc Becane; Sylvie Bastuji-Garin; France Leturcq; Catherine Chiron; Jamel Chelly; Romain K Gherardi
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

7.  Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.

Authors:  Sylvie Houde; Michèle Filiatrault; Anne Fournier; Julie Dubé; Sylvie D'Arcy; Denis Bérubé; Yves Brousseau; Guy Lapierre; Michel Vanasse
Journal:  Pediatr Neurol       Date:  2008-03       Impact factor: 3.372

Review 8.  Duchenne and Becker muscular dystrophies.

Authors:  Kevin M Flanigan
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

9.  Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.

Authors:  W D Biggar; V A Harris; L Eliasoph; B Alman
Journal:  Neuromuscul Disord       Date:  2006-03-20       Impact factor: 4.296

10.  Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.

Authors:  Valeria Ricotti; Deborah A Ridout; Elaine Scott; Ros Quinlivan; Stephanie A Robb; Adnan Y Manzur; Francesco Muntoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-12-18       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.